Video Abstract

Video Abstract

Close modal
BACKGROUND AND OBJECTIVES

Anxiety disorder diagnoses in office-based settings increased for children through the mid-2010s, but recent changes in diagnosis and treatment are not well understood. The objectives of the current study were to evaluate recent trends in anxiety disorder diagnosis and treatment among children, adolescents, and young adults.

METHODS

This study used serial cross-sectional data from the National Ambulatory Medical Care Survey (2006–2018), a nationally representative annual survey of US office-based visits. Changes in anxiety disorder diagnosis and 4 treatment categories (therapy alone, therapy and medications, medications alone, or neither) are described across 3 periods (2006–2009, 2010–2013, 2014–2018). Multinomial logistic regression compared differences in treatment categories, adjusting for age group, sex, and race/ethnicity, contrasting the last and middle periods with the first.

RESULTS

The overall proportion of office visits with an anxiety disorder diagnosis significantly increased from 1.4% (95% confidence interval [CI] 1.2–1.7; n = 9 246 921 visits) in 2006 to 2009 to 4.2% (95% CI 3.4–5.2; n = 23 120 958 visits) in 2014 to 2018. The proportion of visits with any therapy decreased from 48.8% (95% CI 40.1–57.6) to 32.6% (95% CI 24.5–41.8), but there was no significant change in the overall use of medications. The likelihood of receiving medication alone during office visits was significantly higher in the last, relative to the first period (relative risk ratio = 2.42, 95% CI 1.24–4.72).

CONCLUSIONS

The proportion of outpatient visits that included a diagnosis of anxiety increased over time, accompanied by a decrease in the proportion of visits with therapy.

What’s Known on This Subject:

The prevalence of anxiety symptoms and unmet treatment needs for anxiety disorder is increasing among children and youth based on national surveys. However, recent studies of trends in office-based therapy or medication prescribing for anxiety disorders are limited to adults.

What This Study Adds:

This study is the first to reveal recent trends in office visit anxiety disorder diagnoses and treatment among children, adolescents, and young adults. The proportion of visits with diagnoses increased while the proportion of those receiving therapy or medication decreased.

Anxiety disorders are the most common mental health condition among children, adolescents, and young adults.1,2 Characteristics of anxiety disorders include persistent worry or fears that occur in different situations or settings and the presence of emotional or physical symptoms that interfere with daily function.3  Untreated anxiety disorders are associated with continued dysfunction, lower educational attainment,4  unemployment or poor job performance,5  and a heightened risk for depression or substance use disorders later in life.57  There are effective psychotherapeutic and psychopharmacologic treatments, but many patients do not receive the care they need.8,9 

Unfortunately, over the past 2 decades, anxiety symptoms have increased for children, adolescents, and young adults,10,11  which has only added to the burden on office-based settings to diagnose and treat anxiety disorders when indicated. The treatment of anxiety disorders appears to lag behind the increase in need, with more parents and other caregivers reporting that anxiety is being diagnosed without follow-up treatment.9  Among adults, recent studies document increases in the diagnosis of anxiety disorder and other mental health conditions in office-based settings, with the lower provision of psychotherapy.12  However, it is unknown whether a similar documented increase in anxiety disorder diagnosis among children, adolescents, and young adults through 201013  has continued in more recent years or whether there were concomitant changes in treatment practice, such as the provision of psychotherapy or medications, for these younger patients.

The objective of the current study was to update our understanding of national trends in practice for diagnosing and treating anxiety disorders in ambulatory care settings for children, adolescents, and young adults. The current study uses the nationally representative National Ambulatory Medical Care Survey (NAMCS) to describe recent trends from 2006 to 2018 in the diagnosis and treatment of anxiety disorders during ambulatory care office visits in the United States.

We conducted a serial cross-sectional analysis of the NAMCS, a yearly, nationally representative survey of office-based physician visits in the United States. Patients 4 to 24 years of age were included in the current study and stratified by age group (4–11 years, 12–17 years, and 18–24 years). Visits with an anxiety disorder diagnosis were defined as having the following diagnostic codes: International Classification of Diseases, 9th Edition 300.0, 300.2, 309.21, 313.23; International Classification of Diseases, 10th Edition F40, F41, F930, and F940. Treatment categories were created on the basis of the NAMCS survey collection tool: (1) psychotherapy or counseling (hereafter, “therapy alone”), (2) therapy and medications, (3) medications alone, and (4) neither therapy nor medication (hereafter, “neither”). Medications included were those commonly used to treat anxiety disorder symptoms for short- or long-term use: antidepressants (selective serotonin reuptake inhibitors [SSRIs], serotonin and norepinephrine reuptake inhibitors [SNRIs], tricyclic antidepressants), benzodiazepines, atypical anxiolytics (buspirone), and antihistamines.14,15  We included all anxiety disorder diagnoses that may be observed among children and youth. Although types of medications used to treat specific diagnoses vary, psychotherapeutic treatment is the recommended first-line treatment of most conditions. SSRIs are to be considered for the treatment of severe social, generalized, separation anxiety, or panic disorder in patients >6 years of age, preferentially in combination with cognitive behavioral therapy. We also explore an alternative definition of the four treatment categories described above using a more limited list of medications (only including SSRI and SNRI).

Consistent with previous longitudinal trend studies using the NAMCS,12,13  data from multiple years were pooled together because of small numbers of visits with anxiety disorder diagnosis for individual years, creating 3 time periods: (1) 2006 to 2009, (2) 2010 to 2013, and (3) 2014 to 2016 and 2018 (NAMCS not released for 2017). We compared differences in treatment categories using multinomial logistic regression, adjusting for age group, sex, and race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, and other) to account for differences over time in sample demographics associated with mental health treatment.16  We included categorical indicator variables for the periods and compared the second and third periods to the first period (referent group) to assess temporal changes in the use of treatments; we considered P values for coefficients to be significant at α <.05. The resulting proportions were weighted to reflect national estimates. The primary analyses were repeated as a sensitivity analysis with the alternative treatment category outcome on the basis of the more limited medication list. All analyses were performed by using StataIC 16 (StataCorp, College Station, TX). This study used publicly available nonidentifiable data and was exempt from institutional review board approval.

There were 1734 visits for anxiety disorder over the study period in the sample, representing a total of 46.4 million office visits with an anxiety disorder diagnosis. The overall proportion of office visits with an anxiety disorder diagnosis significantly increased from 1.4% (95% confidence interval [CI] 1.2–1.7; n = 9 246 921 visits) in 2006 to 2009 to 4.2% (95% CI 3.4–5.2; n = 23 120 958 visits) in 2014 to 2018. The proportion of visits with anxiety disorder diagnosis increased for all age groups, particularly for adolescents (1.4% [95% CI 1.1–1.9] to 4.6% [95% CI 3.3–6.4]) and young adults (2.5% [95% CI 2.1–3.1] to 7.1% [95% CI 5.7–8.9]). The increase in the proportion of child visits with anxiety disorder diagnoses was smaller, from 0.6% (95% CI 0.4–0.9) to 1.5% (95% CI 1.0–2.2). The distribution of patient demographic characteristics across visits with an anxiety disorder diagnosis, including age group, sex, and race/ethnicity, were similar across periods, except for a higher proportion of Hispanic patients in the last period (Table 1). The type of providers for anxiety visits was also similar over time (Table 1).

TABLE 1

Characteristics of Office Visits With Anxiety Disorder Diagnosis by Year

2006–2009, Unweighted n = 374, Weighted n = 9 246 9212010–2013, Unweighted n = 828, Weighted n = 14 012 0372014–2018, Unweighted n = 532, Weighted n = 23 120 986
VariableProportion (%)95% CIProportion (%)95% CIProportion (%)95% CI
Age group, y       
 4–11 16.3 (11.7–22.3) 18.4 (13.9–23.9) 13.3 (9.6–18.1) 
 12–17 28.4 (22.9–34.7) 30.5 (25.8–35.6) 32.4 (26.0–39.6) 
 18–24 55.2 (47.6–62.6) 51.2 (44.3–58.0) 54.3 (46.5–62.0) 
Sex       
 Female 49.3 (43.1–55.6) 53.3 (47.7–58.8) 53.2 (46.1–60.1) 
 Male 50.7 (44.4–56.9) 46.7 (41.2–52.3) 46.8 (39.9–53.9) 
Race/ethnicity       
 White non-Hispanic 81.6 (74.3–87.1) 84.5 (80.0–88.1) 74.5 (66.9–80.9) 
 Black non-Hispanic 6.3 (3.3–11.6) 4.8 (3.1–7.2) 3.6 (2.0–6.6) 
 Hispanic 7.5 (4.4–12.5) 7.7 (5.1–11.6) 17.2 (11.8–24.5) 
 Other 4.6 (2.3–9.0) 3.0 (1.8–4.9) 4.6 (2.4–8.6) 
Provider type       
 Primary care 41.8 (33.2–51.0) 46.5 (37.9–55.4) 46.4 (36.0–57.2) 
 Surgical care 1.0 (0.3–4.1) 0.2 (0.0–1.7) 1.0 (0.4–2.7) 
 Medical care 57.1 (48.3–65.5) 53.2 (44.4–61.9) 52.6 (41.8–63.1) 
Any therapy or medications 79.7 (72.4–85.5) 73.2 (67.1–78.5) 70.7 (62.9–77.5) 
Receipt of therapy 48.8 (40.1–57.6) 39.9 (32.1–48.2) 32.6 (24.5–41.8) 
Any anxiety medication 61.9 (55.0–68.2) 59.4 (54.2–64.4) 61.8 (54.1–68.9) 
Type of anxiety medication       
 SSRI 44.8 (37.9–51.8) 41.1 (35.5–46.8) 46.3 (39.0–53.7) 
 SNRI 8.8 (5.3–14.4) 6.8 (4.3–10.6) 8.1 (4.6–13.9) 
 Tricyclic 0.0 (0.0–0.0) 0.1 (0.0–0.8) 0.5 (0.1–1.9) 
 Benzodiazepine 18.2 (13.5–24.0) 20.6 (16.3–25.7) 13.2 (9.4–18.2) 
 Atypical anxiolytic 2.6 (1.2–5.5) 1.7 (0.9–3.2) 3.4 (1.7–6.8) 
 Antihistamine 0.1 (0.0–0.8) 2.0 (0.9–4.2) 3.6 (1.8–7.0) 
2006–2009, Unweighted n = 374, Weighted n = 9 246 9212010–2013, Unweighted n = 828, Weighted n = 14 012 0372014–2018, Unweighted n = 532, Weighted n = 23 120 986
VariableProportion (%)95% CIProportion (%)95% CIProportion (%)95% CI
Age group, y       
 4–11 16.3 (11.7–22.3) 18.4 (13.9–23.9) 13.3 (9.6–18.1) 
 12–17 28.4 (22.9–34.7) 30.5 (25.8–35.6) 32.4 (26.0–39.6) 
 18–24 55.2 (47.6–62.6) 51.2 (44.3–58.0) 54.3 (46.5–62.0) 
Sex       
 Female 49.3 (43.1–55.6) 53.3 (47.7–58.8) 53.2 (46.1–60.1) 
 Male 50.7 (44.4–56.9) 46.7 (41.2–52.3) 46.8 (39.9–53.9) 
Race/ethnicity       
 White non-Hispanic 81.6 (74.3–87.1) 84.5 (80.0–88.1) 74.5 (66.9–80.9) 
 Black non-Hispanic 6.3 (3.3–11.6) 4.8 (3.1–7.2) 3.6 (2.0–6.6) 
 Hispanic 7.5 (4.4–12.5) 7.7 (5.1–11.6) 17.2 (11.8–24.5) 
 Other 4.6 (2.3–9.0) 3.0 (1.8–4.9) 4.6 (2.4–8.6) 
Provider type       
 Primary care 41.8 (33.2–51.0) 46.5 (37.9–55.4) 46.4 (36.0–57.2) 
 Surgical care 1.0 (0.3–4.1) 0.2 (0.0–1.7) 1.0 (0.4–2.7) 
 Medical care 57.1 (48.3–65.5) 53.2 (44.4–61.9) 52.6 (41.8–63.1) 
Any therapy or medications 79.7 (72.4–85.5) 73.2 (67.1–78.5) 70.7 (62.9–77.5) 
Receipt of therapy 48.8 (40.1–57.6) 39.9 (32.1–48.2) 32.6 (24.5–41.8) 
Any anxiety medication 61.9 (55.0–68.2) 59.4 (54.2–64.4) 61.8 (54.1–68.9) 
Type of anxiety medication       
 SSRI 44.8 (37.9–51.8) 41.1 (35.5–46.8) 46.3 (39.0–53.7) 
 SNRI 8.8 (5.3–14.4) 6.8 (4.3–10.6) 8.1 (4.6–13.9) 
 Tricyclic 0.0 (0.0–0.0) 0.1 (0.0–0.8) 0.5 (0.1–1.9) 
 Benzodiazepine 18.2 (13.5–24.0) 20.6 (16.3–25.7) 13.2 (9.4–18.2) 
 Atypical anxiolytic 2.6 (1.2–5.5) 1.7 (0.9–3.2) 3.4 (1.7–6.8) 
 Antihistamine 0.1 (0.0–0.8) 2.0 (0.9–4.2) 3.6 (1.8–7.0) 

The overall proportion of visits with therapy alone or therapy and medications decreased from 48.8% (95% CI 40.1–57.6; n = 4 513 468 visits) to 32.6% (95% CI 24.5–41.8; n = 7 536 619 visits) in the first to last periods, respectively (Table 1). However, the overall proportion of visits with medication prescribed did not differ by period, and in the last period, medications were prescribed in 61.8% (95% CI 54.1–68.9; n = 14 286 916) of all visits. Among those prescribed medications, the most prescribed medications were SSRIs (46.3%), benzodiazepines (13.2%), SNRIs (8.1%), and antihistamines (3.6%). Types of medications prescribed were also consistent over time, except for antihistamines, which increased from 0.1% (95% CI 0.0–0.8) in 2006 to 2009 to 3.6% (95% CI 1.8–7.0) in 2014 to 2018.

When examining differences by period in the 4 treatment categories, the proportion of visits receiving neither medication nor therapy increased over time for all age groups, as did the proportion of visits receiving medications alone (Fig 1). Relative to therapy only, the likelihood of having neither therapy nor medications was significantly greater for the last period compared with the first period (relative risk ratio = 2.70, 95% CI 1.33–5.47; P <.01), as was having medication only (relative risk ratio = 2.42, 95% CI 1.24–4.72; P = .01). However, there were no significant differences for the second period compared with the first period. In addition, there were no differences for any period in the likelihood of combined therapy relative to therapy only. The differences by period were similar when the alternative definition of medications (including SSRI and SNRI only) was used to derive treatment categories (Supplemental Fig 2).

FIGURE 1

Treatment type by age and year.

FIGURE 1

Treatment type by age and year.

Close modal

Anxiety disorder was more frequently diagnosed over time among a representative sample of US office-based visits for children, adolescents, and young adults. In addition, the proportion cof office visits for anxiety disorders with any type of treatment at the visit decreased over time. However, overall medication prescribing was largely stable, and there was little hange in the types of medications prescribed, except for changes in antihistamine prescribing. As a result, a larger proportion of visits received either medication alone or no treatment. Medications are recommended as either first-line or adjunct treatment for those receiving therapy for anxiety disorders.14 

Previously reported declines in receipt of office-based therapy for mental health conditions among adults12,17  extend to young patients with anxiety disorder through 2018. The low use of psychosocial care with pharmacotherapy for mental health conditions has been documented previously among children.1820  Findings from the current study reveal a gap in the quality of care for patients with anxiety disorders, which could worsen with the increasing prevalence of anxiety.9,13,21  If the volume of children and adolescents with anxiety disorders continues to increase, the health system, in which most young patients are already receiving medications alone or neither medication nor therapy during office-based visits, would be further taxed.

There are several potential explanations for the trends in anxiety disorder treatments observed in the study with important implications for policy and practice. First, the absolute number of visits with a diagnosis of anxiety disorders increased, meaning that office-based settings treated patients with an anxiety disorder at levels that may have exceeded their capacities to deliver in-office counseling. If they could not counsel these patients, providers could give them medications alone or no treatment. Alternatively, there could be secular trends in behavioral health prescribing practices that favor medication, which could be due to marketing,22  incentives or reimbursement practices,23  or caregiver/patient preferences.24  Recent changes in prescribing for mental health conditions have been documented elsewhere, with rates of antidepressant prescribing increasing in recent years in Medicaid and commercially insured children and youth.25  With the recent recommendations for universal anxiety screening in primary care settings by the US Preventive Services Task Force,26  the prevalence of clinically recognized anxiety disorder may increase even further and exacerbate quality concerns for anxiety disorder treatment if not implemented with additional integrated treatment resources.

This study relied on provider reports and diagnoses, which are likely to under-identify patients with anxiety disorders, and we lack information about the care patients received after or before these visits. Second, we do not have information on the specific type of psychotherapy or counseling recommended or delivered. Thus, we cannot comment on whether the therapies delivered were evidence-based. In addition, the medications prescribed may not be the preferred medications for treating anxiety disorder in all cases. However, our description captures routine practice in office-based settings. Third, although we adjusted for demographic characteristics in our regression model, we cannot rule out the possibility that variation in other unobserved patient characteristics in the cross-sectional patient visit samples over time may contribute to the changes in the treatment categories we observed. Finally, we used a broad age range of children, adolescents, and young adults, and age-specific guidelines do differ. However, our goal was to broadly describe the treatment of anxiety disorders across a range of ages to describe trends in office-based settings. Future research could examine how prescribing varied over time in delivering age-specific treatment guidelines.

The reduction in therapy during office visits and the greater reliance on medications for anxiety disorders may reflect growing resource constraints in office settings in the context of a child and youth mental health crisis that has been building over time.1  Further research is needed to investigate how reliance on medications has evolved during the coronavirus disease 2019 pandemic and whether these trends have continued or worsened.

Dr Chavez conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript; Drs Gardner, Pajer, Rosic, Kemper, and Kelleher and Ms Tyson contributed to the concept and design of the study, reviewed, and contributed to the initial draft of the manuscript, and critically revised the manuscript; and all authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

FUNDING: No external funding.

CONFLICT OF INTEREST DISCLOSURES: The authors have indicated they have no potential conflicts of interest relevant to this article to disclose.

CI

confidence interval

NAMCS

National Ambulatory Care Medical Survey

SNRI

serotonin and norepinephrine reuptake inhibitor

SSRI

selective serotonin reuptake inhibitor

1
Bitsko
RH
,
Claussen
AH
,
Lichstein
J
, et al;
Contributor
.
Mental health surveillance among children - United States, 2013–2019
.
MMWR Suppl
.
2022
;
71
(
2
):
1
42
2
Kessler
RC
,
Avenevoli
S
,
Costello
EJ
, et al
.
Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement
.
Arch Gen Psychiatry
.
2012
;
69
(
4
):
372
380
3
American Psychiatric Association
.
Diagnostic and Statistical Manual of Mental Disorders
, 5th ed.
Washington, DC
:
American Psychiatric Association
;
2013
4
Mojtabai
R
,
Stuart
EA
,
Hwang
I
, et al
.
Long-term effects of mental disorders on educational attainment in the National Comorbidity Survey ten-year follow-up
.
Soc Psychiatry Psychiatr Epidemiol
.
2015
;
50
(
10
):
1577
1591
5
Essau
CA
,
Lewinsohn
PM
,
Olaya
B
,
Seeley
JR
.
Anxiety disorders in adolescents and psychosocial outcomes at age 30
.
J Affect Disord
.
2014
;
163
:
125
132
6
Lopez
B
,
Turner
RJ
,
Saavedra
LM
.
Anxiety and risk for substance dependence among late adolescents/young adults
.
J Anxiety Disord
.
2005
;
19
(
3
):
275
294
7
Bushnell
GA
,
Gaynes
BN
,
Compton
SN
, et al
.
Incident substance use disorder following anxiety disorder in privately insured youth
.
J Adolesc Health
.
2019
;
65
(
4
):
536
542
8
Ghandour
RM
,
Sherman
LJ
,
Vladutiu
CJ
, et al
.
Prevalence and treatment of depression, anxiety, and conduct problems in US children
.
J Pediatr
.
2019
;
206
:
256
267.e3
9
Lebrun-Harris
LA
,
Ghandour
RM
,
Kogan
MD
,
Warren
MD
.
Five-year trends in US children’s health and well-being, 2016-2020
.
JAMA Pediatr
.
2022
;
176
(
7
):
e220056
e220056
10
Duffy
ME
,
Twenge
JM
,
Joiner
TE
.
Trends in mood and anxiety symptoms and suicide-related outcomes among U.S. undergraduates, 2007-2018: evidence from two national surveys
.
J Adolesc Health
.
2019
;
65
(
5
):
590
598
11
Collishaw
S
.
Annual research review: secular trends in child and adolescent mental health
.
J Child Psychol Psychiatry
.
2015
;
56
(
3
):
370
393
12
Tadmon
D
,
Olfson
M
.
Trends in outpatient psychotherapy provision by U.S. psychiatrists: 1996-2016
.
Am J Psychiatry
.
2022
;
179
(
2
):
110
121
13
Olfson
M
,
Blanco
C
,
Wang
S
, et al
.
National trends in the mental health care of children, adolescents, and adults by office-based physicians
.
JAMA Psychiatry
.
2014
;
71
(
1
):
81
90
14
Walter
HJ
,
Bukstein
OG
,
Abright
AR
, et al
.
Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders
.
J Am Acad Child Adolesc Psychiatry
.
2020
;
59
(
10
):
1107
1124
15
American Academy of Child and Adolescent Psychiatry
.
Anxiety Disorders: Parents’ Medication Guide
.
Washington, DC
:
American Psychiatric Association
;
2020
16
Cummings
JR
,
Ji
X
,
Druss
BG
.
Mental health service use by medicaid-enrolled children and adolescents in primary care safety-net clinics
.
Psychiatr Serv
.
2020
;
71
(
4
):
328
336
17
Mojtabai
R
,
Olfson
M
.
National trends in psychotherapy by office-based psychiatrists
.
Arch Gen Psychiatry
.
2008
;
65
(
8
):
962
970
18
Ali
MM
,
Sherman
LJ
,
Lynch
S
, et al
.
Differences in utilization of mental health treatment among children and adolescents with Medicaid or private insurance
.
Psychiatr Serv
.
2019
;
70
(
4
):
329
332
19
Finnerty
M
,
Neese-Todd
S
,
Pritam
R
, et al
.
Access to psychosocial services prior to starting antipsychotic treatment among medicaid-insured youth
.
J Am Acad Child Adolesc Psychiatry
.
2016
;
55
(
1
):
69
76.e3
20
Bushnell
GA
,
Dusetzina
SB
,
Compton
SN
, et al
.
Psychotherapy claims surrounding pharmacotherapy initiation in children and adolescents with anxiety disorders
.
J Child Adolesc Psychopharmacol
.
2019
;
29
(
2
):
100
106
21
Bitsko
RH
,
Holbrook
JR
,
Ghandour
RM
, et al
.
Epidemiology and impact of health care provider-diagnosed anxiety and depression among US children
.
J Dev Behav Pediatr
.
2018
;
39
(
5
):
395
403
22
Hadland
SE
,
Cerdá
M
,
Earlywine
JJ
, et al
.
Analysis of pharmaceutical industry marketing of stimulants, 2014 through 2018
.
JAMA Pediatr
.
2020
;
174
(
4
):
385
387
23
Kelleher
KJ
,
Rubin
D
,
Hoagwood
K
.
Policy and practice innovations to improve prescribing of psychoactive medications for children
.
Psychiatr Serv
.
2020
;
71
(
7
):
706
712
24
Fiks
AG
,
Mayne
S
,
Debartolo
E
, et al
.
Parental preferences and goals regarding ADHD treatment
.
Pediatrics
.
2013
;
132
(
4
):
692
702
25
Zito
JM
,
Pennap
D
,
Safer
DJ
.
Antidepressant use in Medicaid-insured youth: trends, covariates, and future research needs
.
Front Psychiatry
.
2020
;
11
:
113
26
Mangione
CM
,
Barry
MJ
,
Nicholson
WK
, et al;
US Preventive Services Task Force
.
Screening for anxiety in children and adolescents: US Preventive Services Task Force recommendation statement
.
JAMA
.
2022
;
328
(
14
):
1438
1444

Supplementary data